APO Research
Talk to an analyst

APO RESEARCH · REPORT

Proprotein Convertase Subtilisin & Kexin Type 9

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchProprotein Convertase Subtilisin & Kexin Type 9 Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Proprotein Convertase Subtilisin & Kexin Type 9 Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Proprotein Convertase Subtilisin & Kexin Type 9 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Proprotein Convertase Subtilisin & Kexin Type 9 Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Proprotein Convertase Subtilisin & Kexin Type 9 Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Proprotein Convertase Subtilisin & Kexin Type 9 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Proprotein Convertase Subtilisin & Kexin Type 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Proprotein Convertase Subtilisin & Kexin Type 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Proprotein Convertase Subtilisin & Kexin Type 9 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Proprotein Convertase Subtilisin & Kexin Type 9 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Proprotein Convertase Subtilisin & Kexin Type 9 market include Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Novartis AG, Eli Lilly and Co, Pfizer Inc, The Medicines Company, Serometrix LLC, Regeneron Pharmaceuticals Inc, Kowa Co Ltd and Ensemble Therapeutics Corp, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Proprotein Convertase Subtilisin & Kexin Type 9 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Proprotein Convertase Subtilisin & Kexin Type 9 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Proprotein Convertase Subtilisin & Kexin Type 9 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Proprotein Convertase Subtilisin & Kexin Type 9 market.

Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Company

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Novartis AG

Eli Lilly and Co

Pfizer Inc

The Medicines Company

Serometrix LLC

Regeneron Pharmaceuticals Inc

Kowa Co Ltd

Ensemble Therapeutics Corp

Dicerna Pharmaceuticals Inc

Catabasis Pharmaceuticals Inc

BioLingus AG

Bioleaders Corp

Betagenon AB

AFFiRiS AG

Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Type

SX-PCK9

O-304

K-312

DCRPCSK-9

BLSM-201

Others

Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Application

Cardiovascular Disease

Homozugous Familial Hyperchalesterolemia

Liver Disease

Metabolic Syndrome

Others

Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Proprotein Convertase Subtilisin & Kexin Type 9 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Proprotein Convertase Subtilisin & Kexin Type 9 key companies, revenue, market share, and recent developments.

3. To split the Proprotein Convertase Subtilisin & Kexin Type 9 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Proprotein Convertase Subtilisin & Kexin Type 9 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Proprotein Convertase Subtilisin & Kexin Type 9 significant trends, drivers, influence factors in global and regions.

6. To analyze Proprotein Convertase Subtilisin & Kexin Type 9 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proprotein Convertase Subtilisin & Kexin Type 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Proprotein Convertase Subtilisin & Kexin Type 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proprotein Convertase Subtilisin & Kexin Type 9.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Proprotein Convertase Subtilisin & Kexin Type 9 industry.

Chapter 3: Detailed analysis of Proprotein Convertase Subtilisin & Kexin Type 9 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Proprotein Convertase Subtilisin & Kexin Type 9 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Proprotein Convertase Subtilisin & Kexin Type 9 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Trends Table 2. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Drivers Table 3. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Opportunities and Challenges Table 4. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Restraints Table 5. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Company (2021-2026) Table 7. Global Proprotein Convertase Subtilisin & Kexin Type 9 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Proprotein Convertase Subtilisin & Kexin Type 9 Key Company Manufacturing Base & Headquarters Table 9. Global Proprotein Convertase Subtilisin & Kexin Type 9 Company, Product Type & Application Table 10. Global Proprotein Convertase Subtilisin & Kexin Type 9 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Proprotein Convertase Subtilisin & Kexin Type 9 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of SX-PCK9 Table 15. Significant Companies of O-304 Table 16. Significant Companies of K-312 Table 17. Significant Companies of DCRPCSK-9 Table 18. Significant Companies of BLSM-201 Table 19. Significant Companies of Others Table 20. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type (2021-2026) Table 24. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Cardiovascular Disease Table 26. Significant Companies of Homozugous Familial Hyperchalesterolemia Table 27. Significant Companies of Liver Disease Table 28. Significant Companies of Metabolic Syndrome Table 29. Significant Companies of Others Table 30. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Application (2021-2026) & (US$ Million) Table 32. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Application (2027-2032) & (US$ Million) Table 33. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application (2021-2026) Table 34. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application (2027-2032) Table 35. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Region (2021-2026) & (US$ Million) Table 37. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Region (2021-2026) Table 38. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Region (2027-2032) & (US$ Million) Table 39. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Region (2027-2032) Table 40. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Country (2021-2026) & (US$ Million) Table 42. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Market Share by Country (2021-2026) Table 43. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Country (2027-2032) & (US$ Million) Table 44. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Market Share by Country (2027-2032) Table 45. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Information Table 46. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview Table 47. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 49. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Development Table 50. Novartis AG Company Information Table 51. Novartis AG Business Overview Table 52. Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 54. Novartis AG Recent Development Table 55. Eli Lilly and Co Company Information Table 56. Eli Lilly and Co Business Overview Table 57. Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 59. Eli Lilly and Co Recent Development Table 60. Pfizer Inc Company Information Table 61. Pfizer Inc Business Overview Table 62. Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 64. Pfizer Inc Recent Development Table 65. The Medicines Company Company Information Table 66. The Medicines Company Business Overview Table 67. The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 69. The Medicines Company Recent Development Table 70. Serometrix LLC Company Information Table 71. Serometrix LLC Business Overview Table 72. Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 74. Serometrix LLC Recent Development Table 75. Regeneron Pharmaceuticals Inc Company Information Table 76. Regeneron Pharmaceuticals Inc Business Overview Table 77. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 79. Regeneron Pharmaceuticals Inc Recent Development Table 80. Kowa Co Ltd Company Information Table 81. Kowa Co Ltd Business Overview Table 82. Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 84. Kowa Co Ltd Recent Development Table 85. Ensemble Therapeutics Corp Company Information Table 86. Ensemble Therapeutics Corp Business Overview Table 87. Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 89. Ensemble Therapeutics Corp Recent Development Table 90. Dicerna Pharmaceuticals Inc Company Information Table 91. Dicerna Pharmaceuticals Inc Business Overview Table 92. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 94. Dicerna Pharmaceuticals Inc Recent Development Table 95. Catabasis Pharmaceuticals Inc Company Information Table 96. Catabasis Pharmaceuticals Inc Business Overview Table 97. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 99. Catabasis Pharmaceuticals Inc Recent Development Table 100. BioLingus AG Company Information Table 101. BioLingus AG Business Overview Table 102. BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 104. BioLingus AG Recent Development Table 105. Bioleaders Corp Company Information Table 106. Bioleaders Corp Business Overview Table 107. Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 109. Bioleaders Corp Recent Development Table 110. Betagenon AB Company Information Table 111. Betagenon AB Business Overview Table 112. Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 114. Betagenon AB Recent Development Table 115. AFFiRiS AG Company Information Table 116. AFFiRiS AG Business Overview Table 117. AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 119. AFFiRiS AG Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Proprotein Convertase Subtilisin & Kexin Type 9 Product Image Figure 2. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2021-2032) & (US$ Million) Figure 4. Global Proprotein Convertase Subtilisin & Kexin Type 9 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. SX-PCK9 Image Figure 8. O-304 Image Figure 9. K-312 Image Figure 10. DCRPCSK-9 Image Figure 11. BLSM-201 Image Figure 12. Others Image Figure 13. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type (2021-2032) Figure 16. Cardiovascular Disease Image Figure 17. Homozugous Familial Hyperchalesterolemia Image Figure 18. Liver Disease Image Figure 19. Metabolic Syndrome Image Figure 20. Others Image Figure 21. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share 2021 VS 2025 VS 2032 Figure 23. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application (2021-2032) Figure 24. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 25. Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 26. North America Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032) & (US$ Million) Figure 27. North America Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032) & (US$ Million) Figure 29. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032) & (US$ Million) Figure 31. Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 32. South America Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032) & (US$ Million) Figure 33. South America Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032) & (US$ Million) Figure 35. Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country (%), 2025 VS 2032 Figure 36. USA Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. USA Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. USA Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Canada Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Canada Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Canada Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Mexico Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Mexico Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Mexico Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Germany Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Germany Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Germany Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. France Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. France Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. France Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. U.K. Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. U.K. Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. U.K. Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Italy Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Italy Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Italy Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Spain Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Spain Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Spain Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Russia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Russia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Russia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Netherlands Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Netherlands Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Netherlands Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Nordic Countries Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Nordic Countries Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Nordic Countries Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. China Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. China Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. China Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Japan Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Japan Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Japan Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. South Korea Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. South Korea Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. South Korea Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. India Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. India Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. India Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Australia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Australia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Australia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Southeast Asia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Southeast Asia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Southeast Asia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Brazil Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Brazil Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Brazil Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Argentina Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Argentina Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Argentina Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Chile Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Chile Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Chile Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Colombia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Colombia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Colombia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Peru Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Peru Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Peru Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Saudi Arabia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Saudi Arabia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Israel Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Israel Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Israel Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. UAE Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. UAE Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. UAE Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Turkey Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Turkey Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Turkey Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Iran Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Iran Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Iran Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Egypt Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Egypt Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Egypt Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Years Considered Figure 121. Research Process Figure 122. Key Executives Interviewed

Scope & coverage.

Types
  • SX-PCK9
  • O-304
  • K-312
  • DCRPCSK-9
  • BLSM-201
  • Others
Applications
  • Cardiovascular Disease
  • Homozugous Familial Hyperchalesterolemia
  • Liver Disease
  • Metabolic Syndrome
  • Others
Companies covered
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Novartis AG
  • Eli Lilly and Co
  • Pfizer Inc
  • The Medicines Company
  • Serometrix LLC
  • Regeneron Pharmaceuticals Inc
  • Kowa Co Ltd
  • Ensemble Therapeutics Corp
  • Dicerna Pharmaceuticals Inc
  • Catabasis Pharmaceuticals Inc
  • BioLingus AG
  • Bioleaders Corp
  • Betagenon AB
  • AFFiRiS AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Proprotein Convertase Subtilisin & Kexin Type 9 Market Dynamics
  1. 2.1 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Trends
  2. 2.2 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Drivers
  3. 2.3 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Opportunities and Challenges
  4. 2.4 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Restraints
3 Proprotein Convertase Subtilisin & Kexin Type 9 Market by Company
  1. 3.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Company Revenue Ranking in 2025
  2. 3.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Company (2021-2026)
  3. 3.3 Global Proprotein Convertase Subtilisin & Kexin Type 9 Company Ranking (2024-2026)
  4. 3.4 Global Proprotein Convertase Subtilisin & Kexin Type 9 Company Manufacturing Base and Headquarters
  5. 3.5 Global Proprotein Convertase Subtilisin & Kexin Type 9 Company Product Type and Application
  6. 3.6 Global Proprotein Convertase Subtilisin & Kexin Type 9 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Proprotein Convertase Subtilisin & Kexin Type 9 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Proprotein Convertase Subtilisin & Kexin Type 9 Market by Type
  1. 4.1 Proprotein Convertase Subtilisin & Kexin Type 9 Type Introduction
  2. 4.1.1 SX-PCK9
  3. 4.1.2 O-304
  4. 4.1.3 K-312
  5. 4.1.4 DCRPCSK-9
  6. 4.1.5 BLSM-201
  7. 4.1.6 Others
  8. 4.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Type
  9. 4.2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Type (2021-2032)
  11. 4.2.3 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type (2021-2032)
5 Proprotein Convertase Subtilisin & Kexin Type 9 Market by Application
  1. 5.1 Proprotein Convertase Subtilisin & Kexin Type 9 Application Introduction
  2. 5.1.1 Cardiovascular Disease
  3. 5.1.2 Homozugous Familial Hyperchalesterolemia
  4. 5.1.3 Liver Disease
  5. 5.1.4 Metabolic Syndrome
  6. 5.1.5 Others
  7. 5.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Application
  8. 5.2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Application (2021-2032)
  10. 5.2.3 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application (2021-2032)
6 Proprotein Convertase Subtilisin & Kexin Type 9 Regional Value Analysis
  1. 6.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032)
  7. 6.3.2 North America Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032)
  10. 6.4.2 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032)
  16. 6.6.2 South America Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Country, 2025 VS 2032
7 Proprotein Convertase Subtilisin & Kexin Type 9 Country-level Value Analysis
  1. 7.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Proprotein Convertase Subtilisin & Kexin Type 9 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  2. 8.1.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Information
  3. 8.1.2 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview
  4. 8.1.3 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  6. 8.1.5 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Eli Lilly and Co
  14. 8.3.1 Eli Lilly and Co Company Information
  15. 8.3.2 Eli Lilly and Co Business Overview
  16. 8.3.3 Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  18. 8.3.5 Eli Lilly and Co Recent Developments
  19. 8.4 Pfizer Inc
  20. 8.4.1 Pfizer Inc Company Information
  21. 8.4.2 Pfizer Inc Business Overview
  22. 8.4.3 Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  24. 8.4.5 Pfizer Inc Recent Developments
  25. 8.5 The Medicines Company
  26. 8.5.1 The Medicines Company Company Information
  27. 8.5.2 The Medicines Company Business Overview
  28. 8.5.3 The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  30. 8.5.5 The Medicines Company Recent Developments
  31. 8.6 Serometrix LLC
  32. 8.6.1 Serometrix LLC Company Information
  33. 8.6.2 Serometrix LLC Business Overview
  34. 8.6.3 Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  36. 8.6.5 Serometrix LLC Recent Developments
  37. 8.7 Regeneron Pharmaceuticals Inc
  38. 8.7.1 Regeneron Pharmaceuticals Inc Company Information
  39. 8.7.2 Regeneron Pharmaceuticals Inc Business Overview
  40. 8.7.3 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  42. 8.7.5 Regeneron Pharmaceuticals Inc Recent Developments
  43. 8.8 Kowa Co Ltd
  44. 8.8.1 Kowa Co Ltd Company Information
  45. 8.8.2 Kowa Co Ltd Business Overview
  46. 8.8.3 Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  48. 8.8.5 Kowa Co Ltd Recent Developments
  49. 8.9 Ensemble Therapeutics Corp
  50. 8.9.1 Ensemble Therapeutics Corp Company Information
  51. 8.9.2 Ensemble Therapeutics Corp Business Overview
  52. 8.9.3 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  54. 8.9.5 Ensemble Therapeutics Corp Recent Developments
  55. 8.10 Dicerna Pharmaceuticals Inc
  56. 8.10.1 Dicerna Pharmaceuticals Inc Company Information
  57. 8.10.2 Dicerna Pharmaceuticals Inc Business Overview
  58. 8.10.3 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  60. 8.10.5 Dicerna Pharmaceuticals Inc Recent Developments
  61. 8.11 Catabasis Pharmaceuticals Inc
  62. 8.11.1 Catabasis Pharmaceuticals Inc Company Information
  63. 8.11.2 Catabasis Pharmaceuticals Inc Business Overview
  64. 8.11.3 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  66. 8.11.5 Catabasis Pharmaceuticals Inc Recent Developments
  67. 8.12 BioLingus AG
  68. 8.12.1 BioLingus AG Company Information
  69. 8.12.2 BioLingus AG Business Overview
  70. 8.12.3 BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  72. 8.12.5 BioLingus AG Recent Developments
  73. 8.13 Bioleaders Corp
  74. 8.13.1 Bioleaders Corp Company Information
  75. 8.13.2 Bioleaders Corp Business Overview
  76. 8.13.3 Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  78. 8.13.5 Bioleaders Corp Recent Developments
  79. 8.14 Betagenon AB
  80. 8.14.1 Betagenon AB Company Information
  81. 8.14.2 Betagenon AB Business Overview
  82. 8.14.3 Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  84. 8.14.5 Betagenon AB Recent Developments
  85. 8.15 AFFiRiS AG
  86. 8.15.1 AFFiRiS AG Company Information
  87. 8.15.2 AFFiRiS AG Business Overview
  88. 8.15.3 AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  90. 8.15.5 AFFiRiS AG Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst